US2008131443A1PendingUtilityA1
Method and composition for reconforming multi-epitopic antigens to intiate an immune response
Est. expiryMay 15, 2016(expired)· nominal 20-yr term from priority
C07K 2317/76C07K 2317/622A61K 2039/505A61P 37/04C07K 16/303C07K 2317/55C07K 16/4266C07K 16/3069A61P 35/00A61K 39/39558C07K 2317/732C07K 2317/734A61K 39/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention concerns methods and compositions for initiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.
Claims
exact text as granted — not AI-modified1 . A method for treating cancer comprising
contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.
2 . The method of claim 1 wherein the binding reagent comprises a monoclonal antibody.
3 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 125.
4 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 19.9.
5 . The method of claim 2 wherein the target multi-epitopic tumor associated antigen is CA 15.3.
6 . The method of claim 1 wherein the tumor-associated antigen is an ovarian tumor antigen.
7 . The method of claim 1 wherein the host immune response is a cellular immune response.
8 . The method of claim 1 wherein the host immune response is a humoral immune response.
9 . The method of claim 1 wherein the host immune response is both a humoral immune response and a cellular response.
10 . A method for eliciting an immune response comprising
contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.
11 . A method for increasing the immunogenicity of an antigen comprising
contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.
12 . A method for re-conforming a multi-epitopic tumor associated antigen expressed in a host serum and for recognizing and initiating an immune response, comprising contacting a multi-epitopic tumor-associated antigen expressed in the host serum with a composition comprising a binding reagent that specifically binds to a single epitope on the tumor-associated antigen; and
allowing the binding reagent to bind to the antigen to form a reagent-antigen pair, whereby the formation of the reagent-antigen pair elicits a host immune response.
13 . A delivery system for a multi-epitopic tumor associated antigen expressed in a host serum, and for recognizing and initiating an immune response, comprising a composition comprising a binding reagent that specifically binds to a single epitope on a multi-epitopic tumor-associated antigen.
14 . The method of claim 1 wherein the formation of the reagent-antigen pair elicits a host immune response that overcomes tolerance of the antigen.
15 . The method of claim 1 wherein the contacting step is ex vivo or in vivo.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.